Evotec SE Posts Weak Q1 2026 but Doubles Down on ‘Horizon’ Transformation and Mid-Term Growth Targets

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Evotec AG ( (EVO) ) has provided an update. Evotec SE reported first-quarter 2026 results on May 6, showing a 22% year-on-year revenue decline to €156.6 million and an adjusted Group EBITDA loss of €21.9 million, reflecting continued softness in drug discovery and development and lower revenues at Just – Evotec Biologics after a one-off Sandoz license payment in early 2025. Despite the weak start, management confirmed full-year 2026 guidance and a 2026–2030 growth framework, expecting revenues to exceed €1 billion and EBITDA margins above 20% by 2030, underpinned by structural savings and a strategic focus on higher-value segments. Operationally, Evotec advanced several technology-enabled and global health partnerships in the quarter, including a BARDA project on Ebola antibodies, a Gates Foundation-backed AI initiative for monoclonal antibodies, and a $10 million milestone from Bristol Myers Squibb under a protein degradation collaboration. The company also launched its ‘Horizon’ transformation phase in March, streamlining its global footprint to 10 sites, creating centers of excellence, overhauling commercial execution, and targeting about €75 million in run-rate savings by 2027 at the cost of approximately €100 million in restructuring charges between 2026 and 2028. After the quarter-end, Evotec strengthened its leadership bench by appointing new chief commercial and operating officers and transitioning the CFO role to Claire Hinshelwood as of May 1, 2026. In addition, the company expects to receive roughly $100 million in cash from its equity stake in Tubulis following the latter’s acquisition by Gilead Sciences, with the potential for further contingent payments, bolstering liquidity and providing financial flexibility during its multi-year transformation. The most recent analyst rating on (EVO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page. Spark’s Take on EVO Stock According to Spark, TipRanks’ AI Analyst, EVO is a Neutral. The score is held down primarily by weak financial performance (persistent losses and negative free cash flow) and bearish longer-term technicals (below key moving averages, negative MACD). The earnings call adds partial support via cost-savings progress, strong biologics performance, and liquidity, but 2026 transition-year guidance and D&PD weakness temper the outlook; valuation is also constrained by negative earnings and no dividend yield. To see Spark’s full report on EVO stock, click here. More about Evotec AG Evotec SE is a Germany-based life sciences company that operates as a drug discovery and development partner and biologics manufacturer for the global pharmaceutical and biotechnology industry. Through its D&PD segment and Just – Evotec Biologics unit, the company focuses on technology-enabled partnerships, biologics development and manufacturing, and global health initiatives for clients worldwide. Average Trading Volume: 149,940 Technical Sentiment Signal: Strong Sell Current Market Cap: $1.11B Learn more about EVO stock on TipRanks’ Stock Analysis page.